Phaarmasia share price
BSE: 523620Pharmaceuticals & BiotechnologySmall Cap
Phaarmasia Limited. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1992
Last close ₹89.00up ₹6.00 (7.23%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹83.00.
29 Oct: open ₹83.00, high ₹89.00, low ₹83.00
52-week range of traded prices to 29 Oct 2026
₹30.32Low, 3 Nov 2025₹131.75High, 12 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹61 Cr3,202nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.44
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹19 crore of one-off items, the largest of them in the quarter to Dec 2025.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.75
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 114.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹19 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 323
Results
Standalone; ₹ crore.Phaarmasia quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +111.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8.28 Crup 7.13%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹0.34 CrQuarter to Mar 2026: −₹0.70 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 4.1%
Revenue by quarter
Peak revenue ₹17 Cr, quarter to Sep 2025; lowest ₹4.72 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Jun 2026, ₹0.34 CrA loss in 4 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.9 | 4.7 | 5.4 | 6.9 | 16.6 | 16.1 | 7.7 | 8.3 |
| Net profit | −0.6 | −0.7 | −0.5 | 0.3 | 1.7 | 16.3 | −0.7 | 0.3 |
| Net margin | −10.8% | −14.8% | −9.7% | 3.9% | 10.5% | 101.4% | −9.1% | 4.1% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹47 Crup 93.72%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹18 CrYear to Mar 2025: −₹1.59 Cr
- Net margin
- 37.2%
Revenue by year
Peak revenue ₹47 Cr, year to Mar 2026; lowest ₹15 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹18 CrA loss in 4 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.9 | 21.4 | 25.7 | 24.5 | 19.9 | 17.2 | 27.5 | 30.6 | 24.4 | 47.2 |
| Net profit | 0.1 | 0.6 | 0.8 | 0.5 | 0.3 | −1.5 | −1.4 | −0.5 | −1.6 | 17.6 |
| Net margin | 0.8% | 2.7% | 3.0% | 2.2% | 1.6% | −9.0% | −5.2% | −1.7% | −6.5% | 37.2% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical formulation, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Phaarmasia PE ratio and valuation
Price to book
At or below today's level on 70% of 1,163 trading days over the last 5 years.
LowestHighest
Its median2.08Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +156.6% | – | – | 0.0% |
| 3 years | +47.6% | – | – | 0.0% |
| 5 years | +24.8% | +123.7% | −44.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Phaarmasia competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Phaarmasia in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Onyx BiotecONYX | 65 | – | 1.18 | +12.1% | −104.3% | −0.4% | – | 0.00% |
 Zenith DrugsZENITHDRUG | 64 | 16.22 | 0.87 | +28.4% | −44.9% | 5.5% | – | 0.00% |
 Sunil HealthcareSUNLOC | 63 | 17.56 | 0.90 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
 Rekvina LaboratoriesVINRKLB | 62 | – | – | – | – | – | −139.0% | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 48 | 98.87 | 2.22 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
 Vivimed LabsVIVIMEDLAB | 47 | – | – | – | – | – | – | 0.00% |
 Mangalam Drugs and OrganicsMANGALAM | 46 | – | 0.45 | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 45 | – | 0.85 | −15.6% | – | −22.8% | −6.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Phaarmasia announcements
Sep 2026
Aug 2026
31 Aug · Legal
Exchange has sought clarification from Phaarmasia Ltd on August 31, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....
Phaarmasia share price by year
Each calendar year to 2025.Phaarmasia share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 112.74 | +132.5% | 112.74 | 24.84 |
| 2024 | 48.50 | +23.2% | 64.53 | 28.10 |
| 2023 | 39.37 | +41.4% | 39.37 | 22.05 |
| 2022 | 27.85 | −15.7% | 37.35 | 21.25 |
| 2021 | 33.05 | −8.2% | 42.00 | 23.50 |
| 2020 | 36.00 | +125.7% | 40.75 | 10.30 |
| 2019 | 15.95 | +5.6% | 22.05 | 12.10 |
| 2018 | 15.10 | −45.5% | 49.20 | 15.00 |
| 2017 | 27.70 | +91.0% | 33.70 | 14.79 |
| 2016 | 14.50 | −45.3% | 33.10 | 14.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 83.00 | 83.00 | 83.00 | 83.00 | 83.00 | 7 |
| 27 Oct 2026 | 83.00 | 91.00 | 82.59 | 83.00 | 83.11 | 9,189 |
| 26 Oct 2026 | 91.29 | 91.29 | 83.01 | 83.10 | 87.41 | 190 |
| 23 Oct 2026 | 96.75 | 96.75 | 89.00 | 91.29 | 95.62 | 231 |
| 22 Oct 2026 | 88.84 | 88.84 | 87.97 | 87.97 | – | 7 |
| 21 Oct 2026 | 80.00 | 87.99 | 80.00 | 87.97 | 83.13 | 283 |
| 16 Oct 2026 | 84.28 | 84.28 | 77.46 | 80.00 | 80.09 | 347 |
| 15 Oct 2026 | 80.86 | 87.50 | 80.86 | 86.00 | 86.34 | 779 |
| 14 Oct 2026 | 80.86 | 80.86 | 80.86 | 80.86 | 80.86 | 2 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 523620
- ISIN
- INE486I01016
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.phaarmasia.in
- CIN
- L24239TG1981PLC002915
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1981
- Registered office
- P No. 147, IDA, Phase V, IDA Jeedimetla, Tirumalagiri, Hyderabad 500055, Telangana
- Share registrar
- Venture Capital & Corporate Investments Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments